viernes, 10 de marzo de 2017

Targeted Immunotherapy for Pancreatic Cancer

View Clinical Trial NCT02810418 - National Cancer Institute
National Cancer Institute banner

This phase I/II trial is for patients with advanced pancreatic cancer. The goal is to determine the best dose of immunotherapy drug LMB-100 and see how well it works when given with nab-paclitaxel, a standard chemotherapy used for pancreatic cancer.

LMB-100 and Nab-Paclitaxel in Treating Patients with Recurrent, Metastatic, and/or Locally Advanced Pancreatic Cancer

No hay comentarios:

Publicar un comentario